Health Canada grants IVD approval to Devyser’s NGS-based chimerism test, the first of its kind in Canada
Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been...
In this paper Dr. Dan Hauzenberger, Medical Director of the Section for Transplantation Immunology at Karolinska University Hospital and Chief Medical Officer at Devyser explains that, monitoring for mixed chimerism in patients after HSCT has in several studies been shown to be of
clinical importance. The main purpose of the assay is
to verify engraftment and subsequently monitor for
the presence of MRD and potentially early detection
of possible relapse.
In this paper Dr. Dan Hauzenberger, Medical Director of the Section for Transplantation Immunology at Karolinska University Hospital and Chief Medical Officer at Devyser explains that, monitoring for mixed chimerism in patients after HSCT has in several studies been shown to be of
clinical importance. The main purpose of the assay is
to verify engraftment and subsequently monitor for
the presence of MRD and potentially early detection
of possible relapse.
Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been...
Read More
Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its...
Read More
Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical...
Read More
Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its...
Read More